NR3C2 nuclear receptor subfamily 3 group C member 2
ENSG00000151623 · protein coding · Open Targets profile
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels. .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, Med-Quality Pocket, Druggable Family
- Antibody
- UniProt loc med conf
- PROTAC
- Database Ubiquitination, Small Molecule Binder
gnomAD loss of function constraint: o/e 0.17363999783992767 (upper bound 0.26736998558044434). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 279 registry trials, updated in the last three years, of the most advanced drugs against NR3C2 (XL550, desoxycorticosterone pivalate, desoxycorticosterone, fludrocortisone, canrenoate, finerenone, felodipine, drospirenone, vamorolone, nimodipine, eplerenone, spironolactone), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Salim ShahSarfez Pharmaceuticals, Inc. · 3 of 3 trials Phase 2+Ph3NCT07046975 · Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactonebrief
- Ahmed s SaadProfessor of OB & GYN · 2 of 2 trials Phase 2+
- Enrico ColliChemo Research SL · 2 of 2 trials Phase 2+
- Hiddo Lambers HeerspinkThe George Institute · 2 of 2 trials Phase 2+
- Nicolas GIRERDCHRU NANCY · 2 of 2 trials Phase 2+
- Peter RossingSteno Diabetes Center Copenhagen · 2 of 2 trials Phase 2+
- Suchitra Krishnan-SarinYale University School of Medicine, Dept of Psychiatry · 2 of 2 trials Phase 2+
- Dirk ElstonMedical University of South Carolina · 1 of 2 trials Phase 2+
- Djillali ANNANEDepartment of medical and surgical Intensive Care Unit, - Raymond Poincaré Hospital - APHP · 1 of 2 trials Phase 2+
- Konstantinos P TsioufisHypertension Unit, First Cardiology Clinic, Hippocration General Hospital, University of Athens, Greece · 1 of 2 trials Phase 2+
- Punyawee UtaipatanacheepChulalongkorn University · 1 of 2 trials Phase 2+
- Adelino Leite-MoreiraUniversidade do Porto · 1 of 1 trials Phase 2+
- Ahmed A AhmedCardiovascular Medicine Department, Assiut University Hospitals · 1 of 1 trials Phase 2+
- Ahmed Essam Abou WardaOctober 6 University · 1 of 1 trials Phase 2+
- Alex NesbittPrincess Alexandra Hospital · 1 of 1 trials Phase 2+
Registry trials of XL550, desoxycorticosterone pivalate, desoxycorticosterone, fludrocortisone, canrenoate, finerenone, felodipine, drospirenone, vamorolone, nimodipine, eplerenone, spironolactone updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 221 of 257 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 22 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
95 trials of drugs against NR3C2 were stopped early; 11 give no reason
Terminated, withdrawn and suspended interventional trials of XL550, desoxycorticosterone pivalate, desoxycorticosterone, fludrocortisone, canrenoate, finerenone, felodipine, drospirenone, vamorolone, nimodipine, eplerenone, spironolactone, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 95.
- withdrawn · 2026-10-29 · Anna Stanhewicz, PhD · Eplerenone“Trainee project; study never initiated”
- terminated · 2026-10-06 · Boehringer Ingelheim · matched by the registry's drug synonyms“Sponsor decision - hold following the evaluation of a safety event. No current sites in the US.”
- terminated · 2026-09-29 · Yale University · matched by the registry's drug synonyms“Slow accrual”
- withdrawn · 2026-09-22 · Sarfez Pharmaceuticals, Inc. · Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone“No recruitment”
- withdrawn · 2026-08-31 · CAMC Health System · Fludrocortisone“Study closed for PI failure to submit renewal paperwork”
- terminated · 2025-12-11 · Jinling Hospital, China · Finerenone (BAY 94-8862)“The patient enrollment rate is proceeding too slowly”
- withdrawn · 2025-11-06 · Brigham and Women's Hospital · Eplerenone“No participants were enrolled in the trial.”
- terminated · 2025-11-04 · University of Texas Southwestern Medical Center · matched by the registry's drug synonyms“The study has been affected significantly by the COVID pandemic, drug supply/drug amendment, low recruitment interest, and FDA approval of another drug with the same indication, so this study has not met its primary endpoint data requirements.”
- terminated · 2025-03-28 · Charite University, Berlin, Germany · Experimental: Spironolactone“No extension of study funding by the DZHK following COVID-19 pandemic-induced prolongation of the recruitment period, also requiring manufacturing of further study drug batches”
- terminated · 2025-03-04 · NHS Greater Glasgow and Clyde · matched by the registry's drug synonyms“The study was stopped due to low recruitment, which the Steering Committee and funder agreed could not be rectified.”
- terminated · 2025-02-24 · Boehringer Ingelheim · matched by the registry's drug synonyms“Company decision”
- terminated · 2024-11-21 · The George Institute · matched by the registry's drug synonyms“Difficulties in recruitment at both sites.”
- terminated · 2024-09-25 · Iain Bressendorff · ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib“Slow recruitment”
- withdrawn · 2024-09-19 · Medical University of South Carolina · Spironolactone 50 MG, Spironolactone 100mg, Spironolactone 200 mg“Lack of funding”
- withdrawn · 2024-09-04 · Medical University of South Carolina · Spironolactone 50Mg Tablet, Spironolactone 100Mg Tablet, Spironolactone 200Mg“Conflict with funding”
- terminated · 2024-06-24 · Assistance Publique Hopitaux De Marseille · Losartan 50 mg and Spironolactone 25 mg pillules oral use“due to an Urgent Security Measure”
- terminated · 2024-05-31 · Henry Ford Health System · matched by the registry's drug synonyms“Insufficient recruitment”
- suspended · 2023-11-18 · Rennes University Hospital · Fludrocortisone“study suspended until new therapeutic units are available”
- terminated · 2023-10-23 · Kevin Flanigan · Spironolactone“Inability to recruit participants.”
- withdrawn · 2023-05-24 · Mayo Clinic · Spironolactone“Administratively closed due to low/no accrual”
- withdrawn · 2023-03-17 · University of Cincinnati · Eplerenone 50 Mg Tab“Unable to recruit subjects”
- withdrawn · 2023-02-21 · University of Michigan · Eplerenone 50mg“Issues relate to COVID-19 and staffing challenges, as well as very tight finances.”
- withdrawn · 2023-02-01 · University of Texas Southwestern Medical Center · Fludrocortisone“This study plan has halted and was withdrawn from the IRB.”
- withdrawn · 2022-08-02 · Wake Forest University Health Sciences · Spironolactone 50 mg“lack of funding”
- terminated · 2022-07-26 · University of North Carolina, Chapel Hill · Drospirenone-Ethinyl Estradiol Oral Tablet“Halted prematurely due to COVID-19-related enrollment challenges.”
Paediatric incentives and obligations for NR3C2's drugs
For XL550, desoxycorticosterone pivalate, desoxycorticosterone, fludrocortisone, canrenoate, finerenone, felodipine, drospirenone, vamorolone, nimodipine, eplerenone, spironolactone: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · NR3C2 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMA/PE/0000244420 (vamorolone, Treatment of Duchenne muscular dystrophy): PM: decision on the application for modification of an agreed PIP, 26 Jun 2025; EMA/PE/0000241538 (finerenone, Treatment of heart failure): PM: decision on the application for modification of an agreed PIP, 16 May 2025; EMA/PE/0000235999 (finerenone, Treatment of chronic kidney disease): PM: decision on the application for modification of an agreed PIP, 14 Apr 2025; EMA/PE/0000184400 (dapagliflozin;eplerenone, Treatment of heart failure): W: decision granting a waiver in all age groups for all conditions or indications, 5 Dec 2024; +10 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/25/3193 positive 9 Jan 2026: Treatment of central serous chorioretinopathy; EU/3/26/3203 positive 23 Feb 2026: Treatment of limbal stem cell deficiency; EU/3/14/1309 positive 22 Aug 2014: Treatment of Duchenne muscular dystrophy; EU/3/15/1554 positive 9 Oct 2015: Treatment of aneurysmal subarachnoid haemorrhageRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Qaialdo: authorised since 26 May 2023; Agamree: authorised since 14 Dec 2023, orphan medicine; Kerendia: authorised since 16 Feb 2022; Lydisilka: authorised since 19 May 2021; +1 moreRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of xl550, desoxycorticosterone pivalate, desoxycorticosterone, fludrocortisone, canrenoate, finerenone, felodipine, drospirenone, vamorolone, nimodipine, eplerenone, spironolactoneRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 88 interventional studies of xl550, desoxycorticosterone pivalate, desoxycorticosterone, fludrocortisone, canrenoate, finerenone, felodipine, drospirenone, vamorolone, nimodipine, eplerenone, spironolactone include patients under 18; 19 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 17 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.